11 reasons for ESA application in hematooncology Review article
Article Sidebar
Main Article Content
Abstract
Symptomatic anemia associated with cancer has a significant impact on the quality of life of the patient, which is one of the prognostic factors for the overall survival. In the case of hematological cancers, anemia occurs more frequently than in solid tumors, both at the time of the diagnosis of the disease and during its treatment. Tumor therapies (especially those used in hematooncology) have significant myelotoxicity, one of which is anemia. The use of ESA (Erythropoiesis Stimulating Agents) in patients with anemia undergoing chemotherapy is a convenient and safe form of therapy. It seems that in many cases ESA could replace transfusions of red blood cell concentrate. The condition for an effective and safe treatment of anemia by ESA in patients undergoing chemotherapy is to use them in accordance with experts recommendations.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Groopman J.E., Itri L.M.: Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. 1999; 91(19): 1616-1634.
3. Ludwig H., Osterborg A.: Pathogenesis and Treatment of Anemia. W: Berenson J. (red.): Biology and Management of Multiple Myeloma. Humana Press 2004: 303-318.
4. Dwilewicz-Trojaczek J.: Niedokrwistość a choroba nowotworowa. Współczesna Onkologia 2004; 8: 15-19.
5. Goldschmidt H., Lannert H., Bommer J. et al.: Multiple myeloma and renal failure. Nephrol. Dial. Transpl. 2000; 15: 301-304.
6. Nemeth E., Valore E., Territo M. et al.: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463.
7. Cucuianu A., Patiu M., Rusu A.: Hepcidin and multiple myeloma related anemia. Medical Hypotheses 2006; 66: 352-354.
8. Wojtukiewicz M.Z., Sierko E., Rybałtowski M. et al.: The Polish Cancer Anemia Survey (POLCAS): a retrospective, multicenter study of 999 cases. Int. J. Hematol. 2009; 89(3): 276-284.
9. Montazeri A.: Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health
Qual. Life Outcomes 2009; 7: 102.
10. Bohlius J., Schmidlin K., Brillant C. et al.: Erythropoietin or Darbepoetin for patients with cancer – meta-analysis based on individual patients data. Cochrane Database Syst. Rev. 2009; (3): CD007303.
11. Österborg A.: Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med. Oncol. 1998; 15(supl. 1): 47-49.
12. Repetto L.: Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Crit. Rev. Oncol. Hematol. 2009; 72(2): 170-179.
13. Radziwon P., Wojtukiewicz M.Z.: Bezpieczne i skuteczne stosowanie składników krwi w onkologii. W: Wojtukiewicz M.Z., Deptała A.: Problemy hematologiczne u chorych na nowotwory. Termedia, Warszawa 2014: 449-475.
14. Radziwon P., Krzakowski M., Kalinka-Warzocha E. et al.: Niedokrwistość u chorych na nowotwory – zalecenia grupy ekspertów. Onkologia w Praktyce Klinicznej 2017; 3(5): 1-10.
15. Castillo J.J., Dalia S., Pascual S.K.: Association between red blood cell transfusion and development of non-Hodgkin lymphoma: a meta-analysis of observational studies. Blood 2010; 116: 2897-2907.
16. NCCN. Cancer and chemotherapy-induced anemia.
17. Rizzo DJ., Brouwers M., Hurley P. et al.: American Society of Clinical Oncology, American Society of Hematology Clinical Practice Guideline Update on the Use Epoetin and Darbepoetin in Adult Patients With Cancer. J. Clin. Oncol. 2010; 28(33): 4996-5010.
18. Schrijvers D., De Samblanx H., Roila F.: Erythropoiesis-stimulating agents in the treatment of anemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann. Oncol. 2010; 21(supl. 5): 244-247.